Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H0I9
UPID:
TKTL2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H0I9; A4FVB4; Q8NCT0; Q96M82
Background:
Transketolase-like protein 2 plays a crucial role in cancer cell metabolism and proliferation. It is essential for total transketolase activity, which is pivotal for the survival and growth of cancer cells. The inhibition of this protein's expression leads to a significant decrease in cancer cell proliferation.
Therapeutic significance:
Understanding the role of Transketolase-like protein 2 could open doors to potential therapeutic strategies. Its critical function in cancer cell metabolism makes it a promising target for developing novel cancer treatments.